CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2018 SGO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Slomovitz Discusses a Study of Everolimus/Letrozole or Hormonal Therapy in Endometrial Cancer
Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative Patients
Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer
Oncology Conference Articles
Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer
First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.
Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib
Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.
Olaparib/Durvalumab Combo Active in Relapsed Ovarian Cancer
Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive,
-mutated ovarian cancer.
Pembrolizumab Plus Niraparib Shows Promise in Ovarian Cancer
Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).
Pembrolizumab Plus Mirvetuximab Soravtansine Active in Ovarian Cancer
Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.
Trastuzumab Active in Uterine Serous Carcinoma
Patients with HER2-positive uterine serous carcinoma had a greater than 50% improvement in progression-free survival when treated with trastuzumab and chemotherapy versus chemotherapy alone, a small randomized trial showed.
ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer
To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.
Low Body Weight, Platelet Counts Predict Niraparib Dose Reductions for Ovarian Cancer
Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Protocol Effects Big Drop in Opioid Use After Gynecologic Surgery
Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.
Checkpoint Inhibitors Induce Higher Rate of Adverse Events in Recurrent Ovarian Cancer
The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.
OncLive News Network On Location: In San Diego Monday, December 3
CAR T-Cell Therapy Shows Early Potential in TNBC
Palbociclib Combo Active in HER2+ Breast Cancer
Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer
FDA Approves Frontline Atezolizumab Regimen for NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.